Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

Medullary thyroid cancer often develops in patients with somatic or germline mutations in RET . Selpercatinib is a novel RET inhibitor. In a phase 1–2 trial, a response to selpercatinib occurred in 38 of 55 previously treated patients (69%) and in 64 of 88 previously untreated patients (73%). Toxic...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 383; no. 9; pp. 825 - 835
Main Authors Wirth, Lori J, Sherman, Eric, Robinson, Bruce, Solomon, Benjamin, Kang, Hyunseok, Lorch, Jochen, Worden, Francis, Brose, Marcia, Patel, Jyoti, Leboulleux, Sophie, Godbert, Yann, Barlesi, Fabrice, Morris, John C, Owonikoko, Taofeek K, Tan, Daniel S.W, Gautschi, Oliver, Weiss, Jared, de la Fouchardière, Christelle, Burkard, Mark E, Laskin, Janessa, Taylor, Matthew H, Kroiss, Matthias, Medioni, Jacques, Goldman, Jonathan W, Bauer, Todd M, Levy, Benjamin, Zhu, Viola W, Lakhani, Nehal, Moreno, Victor, Ebata, Kevin, Nguyen, Michele, Heirich, Dana, Zhu, Edward Y, Huang, Xin, Yang, Luxi, Kherani, Jennifer, Rothenberg, S. Michael, Drilon, Alexander, Subbiah, Vivek, Shah, Manisha H, Cabanillas, Maria E
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 27.08.2020
Subjects
Adolescent
Adult
Aged
Aged, 80 and over
Alanine
Alanine transaminase
Aspartate aminotransferase
Cancer therapies
Collaboration
Diarrhea
FDA approval
Female
Humans
Hypertension - chemically induced
Hyponatremia
Inhibitor drugs
Intention to Treat Analysis
Kaplan-Meier Estimate
Kinases
Male
Metastasis
Middle Aged
Mutants
Mutation
Oncology
Progression-Free Survival
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Proto-Oncogene Proteins c-ret - analysis
Proto-Oncogene Proteins c-ret - antagonists & inhibitors
Proto-Oncogene Proteins c-ret - genetics
Pyrazoles - administration & dosage
Pyrazoles - adverse effects
Pyridines - administration & dosage
Pyridines - adverse effects
Statistical analysis
Survival
Targeted cancer therapy
Thyroid cancer
Thyroid Neoplasms - drug therapy
Transaminases - blood
Treatment Outcome
Tumors
Young Adult
Online AccessGet full text

Cover

More Information
Summary:Medullary thyroid cancer often develops in patients with somatic or germline mutations in RET . Selpercatinib is a novel RET inhibitor. In a phase 1–2 trial, a response to selpercatinib occurred in 38 of 55 previously treated patients (69%) and in 64 of 88 previously untreated patients (73%). Toxic effects were mainly low grade.
Bibliography:VS, MS, MC contributed equally
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2005651